RxDoctor Payments DataLook up a doctor →

Abdulrahman Abdulbaki, MD

Interventional Cardiology · Des Moines, IANPI 1972701050

Payments from drug & device makers

$43,117in general payments, 2019–2025

Across 591 payments — averaging $72.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$29K
  • Medtronic$5K
  • Boston Scientific$2K
  • Abbott$2K
  • Edwards Lifesciences$1K
  • Inari Medical, Inc.$1K
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$26,25061%
  • Travel & lodging$5,20412%
  • Food & beverage$11,56327%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,117 in reported general payments places this provider in the 80th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$249,330
Medicare patients
911
Services billed
2,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban273$247,752
JardianceEmpagliflozin123$111,212
EntrestoSacubitril/Valsartan86$79,298
FarxigaDapagliflozin Propanediol67$57,122
XareltoRivaroxaban66$53,724
Repatha SureclickEvolocumab18$21,187
Atorvastatin Calcium528$3,097
Ranolazine ErRanolazine24$2,935
Metoprolol Succinate280$2,595
Bumetanide63$2,318
ClopidogrelClopidogrel Bisulfate241$2,110
Ezetimibe54$1,613
Losartan Potassium124$968
Lisinopril193$944
Amlodipine Besylate185$888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$107$247,752273 claims
Boehringer IngelheimJardiance$31$111,212123 claims
NovartisEntresto$327$79,29886 claims
AstraZenecaFarxiga$354$57,12267 claims
Johnson & JohnsonXarelto$51$53,72466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →